SAVING LIVES FROM WITHIN BY PROTECTING CELLS

SeaBeLife Biotech

Company  |
France, Roscoff

Primary tabs

About your organization / profile

SeaBeLife pioneers a revolutionary therapeutic paradigm aimed at halving the medical burden, including mortality rates, of severe pathologies lacking effective treatments. Our strategy focuses on developing First-In-Class small Drugs, rooted in a proprietary platform technology comprising small molecules that halt cellular death and forestall organ failure. With a robust pipeline boasting 150 patented molecules exclusively licensed to SeaBeLife, our innovative approach targets critical medical needs. Currently, we are advancing two assets through preclinical development: SBL01, designed to address life-threatening Orphan and Acute Liver Injuries / Failures (ALI/ALF), and SBL03, aiming to preserve vision in Dry-AMD patients, a leading cause of blindness globally among the elderly. These initiatives promise to transform patient outcomes, addressing significant social, economic, and healthcare challenges. 

Network (0)

There are no organizations in the network.

Recent activities

Avatar

SeaBeLife Biotech has taken its fundraising offline. 

Avatar

The dataroom has been updated.

Avatar

The pitchdeck document has been updated in the dataroom.

Avatar

SeaBeLife Biotech has updated its fundraising

Avatar

SeaBeLife Biotech has published fundraising documents

Avatar

Morgane Rousselot has joined SeaBeLife Biotech